RAPID DIAGNOSTIC TESTING (RDT) TECHNOLOGY
In January 2024, WHO and the Medicines Patent Pool (MPP) signed a license agreement with SD Biosensor, Inc. (SDB), a global in-vitro diagnostic company, to provide sublicensees with the right, know-how and material to manufacture SDB’s rapid diagnostic testing (RDT) technology. The transparent, non-exclusive license agreement, negotiated under the auspices of the COVID-19 Technology Access Pool (C-TAP), represents an important milestone in the evolution of the C-TAP initiative as it enables the manufacture of diagnostics for COVID-19 as well as other diseases such as HIV, malaria and syphilis.
A call for applications will be launched shortly.
|Aim of the Licence
To facilitate local manufacture and the development of RDTs for COVID-19 and other diseases.
Any RDT product based on the Licensed Technology, including without limitation the Standard Q COVID-19 Ag Test.
SDB to provide rights to SDB Patents, Material and Know-How that are useful or otherwise relevant for manufacturing of RDT including without limitation for COVID-19 and other RDTs in the Field.
|Field of use
Detection of any antigen, including without limitation for SARS-Cov-2.
Worldwide, except the countries where SDB production plants are located: Brazil, India, Indonesia, Korea, and Panama.
|Scope of the grant
Non-exclusive right under the Licensed Technology for MPP to grant sublicences to develop, make and sell the Products, commercialise, and sell the Product for use in the Territory and in the Field.
|Royalty rates apply on the net sales of the Products where there is a patent right granted and in force in the country of manufacture or sale as follows:
Continuing until, (i) for the countries where exist a Patent Right, the date the last patent right has lapsed, expired, or been invalidated or (ii) for the countries without Patent Rights, which is valid and in force, for a term of ten (10) years.